1 drug(s) with this reaction
1,064 total reports
Pancreatic Carcinoma has been reported as an adverse reaction across 1 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,064 adverse event reports mention pancreatic carcinoma in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with pancreatic carcinoma, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have pancreatic carcinoma listed in their FDA adverse event reports, sorted by report count:
In addition to pancreatic carcinoma, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
1 drug(s) manufactured by Abbvie Inc have pancreatic carcinoma listed in their FDA adverse event reports: PANCRELIPASE.
There are a combined 1,064 reports of pancreatic carcinoma across 1 Abbvie Inc drug(s) in the FDA adverse event database.